Sign in
TerminatedPhase 2

Mechanisms of EPO-induced Hypertension

Key facts

Who runs it
VA Office of Research and Development
Where
Indianapolis, United StatesSee the site
Trial code
Status
Terminated
Phase
Phase 2
People taking part
27 people enrolled
Started
4 Jan 2021
Ended
31 Jul 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Darbepoetin
Record updated
15 December 2025
Why it stopped
The trial was stopped because of inability to reach target sample size.

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Stage 3 or 4 chronic kidney disease
  • Controlled hypertension with 24 hour ambulatory blood pressure monitoring less than 140/90 mmHg at baseline and treatment with at least 1 antihypertensive medication
  • Hemoglobin between 8 and 10 g/dL
  • No treatment with erythropoiesis-stimulating agents (ESA) within 3 previous months

Who cannot take part

  • Need for packed red blood cells (RBC) transfusion in the previous 2 months
  • Myocardial infarction, stroke or hospitalization for heart failure in the past 2 months
  • In the assessment of the investigator, have hematologic, inflammatory, infectious, or other conditions that might interfere with the erythropoietic response

Where in United States

  • Richard L. Roudebush VA Medical Center, Indianapolis, INIndianapolis, United States

About the trial

What the trial wants to find out

The investigators hypothesize that compared to untreated controls, erythropoietin (EPO) therapy in anemic patients with chronic kidney disease will raise diastolic blood pressure (BP). The magnitude of increase in diastolic BP at 12 weeks after treatment will be related to two factors. First, endothelial dysfunction and worsening of endothelial function from baseline to 4 weeks and second, the change of forearm blood flow in response to breathing oxygen and the change in this measure from baseline to 4 weeks. Study procedures include fasting blood draws, ambulatory blood pressure, urine collection, and forearm blood flow tests. The study hopes to accrue 160 subjects.

The 2 groups in the trial

  • Early startExisting treatment, for comparison

    Participants given study drug immediately at randomization

    Treatment: Darbepoetin

  • Delayed startNo study treatment, for comparison

    Participants given study drugs 12 weeks after randomization

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Mechanisms of Erythropoietin Induced Hypertension
Publications
Record updated
15 December 2025